Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martínez Osorio Christian Andrés, Sopeña Sutil Raquel, Vilaseca Cabo Antoni, Linares Espinós Estefanía, Ramírez Backhaus Miguel, Gómez Rivas Juan, Costa Planells Marc, Martinez Breijo Sara, Picola Brau Natalia, Domínguez Estaban Mario, Muñoz Rodríguez Jesús, Sanchís Bonet Angeles, Guijarro Cascales Ana, Beamud Cortés Manel, Servian Vives Pol, de la Morena Gallego José Manuel, Pérez Márquez Meritxell, García Sanz Miguel, Ramón Alemán José, Zamora Horcajada Álvaro, Rodríguez Part Victor, Hassi Roman Mario, Rodriguez Concha Cristian, Rios González Emilio, de Pablos-Rodríguez Pedro
Аннотация
MATERIALS AND METHODS: This multicentre, retrospective study included patients with mHSPC treated with apalutamide plus ADT from May 2018 to January 2025 across 18 Spanish centers. Patients were stratified according to PSA level at 6 months: Complete response (CR; ≤ 0.2 ng/mL) or incomplete response (IR; > 0.2 ng/mL). The primary objective was to evaluate the association between PSA response and rPFS at 24 and 36 months. Univariate and multivariate Cox regression analyses were used to identify predictors of progression.
RESULTS: Among 812 patients, 65% achieved a CR at 6 months, associated with higher rPFS at 24 (94%) and 36 (81%) months compared to the IR group (73% and 60%, respectively; p < 0.0001). CR (hazard ratio: 0.38; p < 0.001) and low-volume disease (hazard ratio: 0.41; p < 0.001) were independent predictors of rPFS. Baseline PSA, disease volume, and positron emission tomography imaging predicted achieving a CR.
CONCLUSIONS: In this large real-world cohort, PSA response at 6 months was a strong predictor of disease progression, supporting its use as a dynamic prognostic biomarker.